A One-Year, Randomized, Open-Label, Parallel-Group, Multiple-Dose Long-Term Safety Study With Controlled Adjustment of Dose of Tapentadol Extended-Release (ER) and Oxycodone Controlled-Release (CR) in Subjects With Chronic, Painful Diabetic Peripheral Neuropathy (DPN).

Trial Profile

A One-Year, Randomized, Open-Label, Parallel-Group, Multiple-Dose Long-Term Safety Study With Controlled Adjustment of Dose of Tapentadol Extended-Release (ER) and Oxycodone Controlled-Release (CR) in Subjects With Chronic, Painful Diabetic Peripheral Neuropathy (DPN).

Discontinued
Phase of Trial: Phase III

Latest Information Update: 05 Sep 2012

At a glance

  • Drugs Oxycodone; Tapentadol
  • Indications Diabetic neuropathies; Neuropathic pain
  • Focus Adverse reactions
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 15 Jul 2010 Planned end date changed from 1 Sep 2012 to 1 Jun 2010 as reported by ClinicalTrials.gov.
    • 15 Jul 2010 Actual patient number is 47 as reported by ClinicalTrials.gov.
    • 20 May 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top